National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pixurvi® is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL).

 

Rapid Review

Commenced Completed Outcome
10/02/2015 20/03/2015 Full Pharmacoeconomic Evaluation Not Recommended